215 related articles for article (PubMed ID: 20701441)
1. Personalized medicine in oncology: tailoring the right drug to the right patient.
Jiang Y; Wang M
Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441
[TBL] [Abstract][Full Text] [Related]
2. Evolution of predictive risk factor analysis for chemotherapy-related toxicity.
Hertz DL; Lustberg MB; Sonis S
Support Care Cancer; 2023 Sep; 31(10):601. PubMed ID: 37773300
[TBL] [Abstract][Full Text] [Related]
3. Advances in point-of-care genetic testing for personalized medicine applications.
de Olazarra AS; Wang SX
Biomicrofluidics; 2023 May; 17(3):031501. PubMed ID: 37159750
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
Das S; Dey MK; Devireddy R; Gartia MR
Sensors (Basel); 2023 Dec; 24(1):. PubMed ID: 38202898
[TBL] [Abstract][Full Text] [Related]
5. Organotypic Models for Functional Drug Testing of Human Cancers.
Huang YL; Dickerson LK; Kenerson H; Jiang X; Pillarisetty V; Tian Q; Hood L; Gujral TS; Yeung RS
BME Front; 2023; 4():0022. PubMed ID: 37849667
[TBL] [Abstract][Full Text] [Related]
6. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
8. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
Parkinson DR; Johnson BE; Sledge GW
Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive biomarkers: tools in personalized oncology.
Nalejska E; Mączyńska E; Lewandowska MA
Mol Diagn Ther; 2014 Jun; 18(3):273-84. PubMed ID: 24385403
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and breast cancer management: current status and perspectives.
Ciccolini J; Fanciullino R; Serdjebi C; Milano G
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):719-29. PubMed ID: 25690018
[TBL] [Abstract][Full Text] [Related]
12. Precision oncology: an overview.
Garraway LA; Verweij J; Ballman KV
J Clin Oncol; 2013 May; 31(15):1803-5. PubMed ID: 23589545
[No Abstract] [Full Text] [Related]
13. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.
Gonzalez de Castro D; Clarke PA; Al-Lazikani B; Workman P
Clin Pharmacol Ther; 2013 Mar; 93(3):252-9. PubMed ID: 23361103
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
15. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
Ogino S; Fuchs CS; Giovannucci E
Expert Rev Mol Diagn; 2012 Jul; 12(6):621-8. PubMed ID: 22845482
[TBL] [Abstract][Full Text] [Related]
16. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in oncology: next generation.
Chiang A; Million RP
Nat Rev Drug Discov; 2011 Dec; 10(12):895-6. PubMed ID: 22129983
[No Abstract] [Full Text] [Related]
18. Personalised cancer medicine.
Jackson SE; Chester JD
Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
[TBL] [Abstract][Full Text] [Related]
19. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines.
Geeleher P; Cox NJ; Huang RS
Genome Biol; 2014 Mar; 15(3):R47. PubMed ID: 24580837
[TBL] [Abstract][Full Text] [Related]
20. Cancer biomarkers: are we ready for the prime time?
Mishra A; Verma M
Cancers (Basel); 2010 Mar; 2(1):190-208. PubMed ID: 24281040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
